富信科技(688662.SH):洪雲等三位高管擬集中競價減持股份
格隆匯3月16日丨富信科技(688662.SH)發佈公吿,因個人資金需求,公司董事兼副總經理洪雲先生計劃以集中競價交易方式減持公司股份不超過6.19萬股,即減持不超過公司總股本的0.0701%;監事會主席梁競新先生計劃以集中競價交易方式減持公司股份不超過2萬股,即減持不超過公司總股本的0.0227%;監事王長河先生計劃以集中競價交易方式減持公司股份不超過2.25萬股,即減持不超過公司總股本的0.0255%。前述減持計劃期間均為2025年4月8日至7月7日(根據中國證券監督管理委員會及上海證券交易所規定禁止減持的期間除外)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.